TriSalus Life Sciences, Inc.
$4.8M 2,429 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Progenics Pharmaceuticals, Inc.
Progenics Pharmaceuticals, Inc. reported $4,776,627.06 across General Payments, Research, and Ownership to 6,457 physicians and teaching hospitals across 6,742 transactions.
- $4.8M Top quartile payer
- All-tracks total
- 6,742 Top quartile volume
- Transactions
- 6,457 Top quartile reach
- Recipients
- +$4.2K
- General Payments vs PY2023
Progenics Pharmaceuticals, Inc. reported $4,776,627.06 across all CMS Open Payments tracks (General + Research + Ownership) to 6,457 physicians and teaching hospitals in Program Year 2024 - ranking #283 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $1,721,728.58, averaging $739.76 per recipient.
How Progenics Pharmaceuticals, Inc.'s $4.8M all-tracks total breaks down
Progenics Pharmaceuticals, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
D
59/100
Total payments
D
54/100
Transaction volume
D
59/100
Physician reach
D
59/100
Payment type diversity
D
63/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer progenics-pharmaceuticals-inc Progenics Pharmaceuticals, Inc.
$4.8M · #283/1,925 · 0.0% industry · PY2024
- TOT $4.8M
- RANK #283
- SHARE 0.0%
- TXN 6,742
- RCP 6,457
- CAT 5
- GEN $1.7M
- ΔGEN +$4.2K
- TOP1 22.3%
- PY 2024
Volume peers
Nearest volume peer: TriSalus Life Sciences, Inc. ($4.8M)
Progenics Pharmaceuticals, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Progenics Pharmaceuticals, Inc.'s CMS-reported General Payments increased by $4.2K (+0.2%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: PROGENICS PHARMACEUTICALS, INC.PY2023: PROGENICS PHARMACEUTICALS, INC.PY2024: PROGENICS PHARMACEUTICALS, INC.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $1,717,513.59
- PY2024
- $1,721,728.58
What the Data Shows for Progenics Pharmaceuticals, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For Progenics Pharmaceuticals, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
Of the 5 general-payment categories charted below, "Compensation for Services Other Than Consulting" is the largest at $851.5K across 214 transactions, 49.5% of this company's General Payments (see our methodology for how research and ownership payments are reported separately).
General Payment Breakdown by Type
"Compensation for Services Other Than Consulting" leads Progenics Pharmaceuticals, Inc.'s 5-category general-payment breakdown at $851.5K, 49.5% of the reported total.
Progenics Pharmaceuticals, Inc. reports 5 general-payment categories - the top three are Compensation for Services Other Than Consulting (49.5%), Consulting Fee (30.4%), and Food and Beverage (11.7%). The remaining 2 categories make up 8.5% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Progenics Pharmaceuticals, Inc. divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Compensation for Services Other Than Consulting | $851.5K | 214 | 49.5% |
| Consulting Fee | $523.1K | 69 | 30.4% |
| Food and Beverage | $200.8K | 5,895 | 11.7% |
| Travel and Lodging | $136.8K | 275 | 7.9% |
| Space Rental or Facility Fees | $9.5K | 4 | 0.6% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $811,558.91 (47.1%) of $1,721,728.58 in this company's General Payments records across 3,590 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Progenics Pharmaceuticals, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
April Harlynn Teitelbaum
$383,599.11 across 29 reported transactions
- 2
Edward Obedian
$111,593.95 across 89 reported transactions
- 3
Giuseppe Esposito
$108,296.72 across 75 reported transactions
- 4
Gary Allan Ulaner
$105,006.11 across 85 reported transactions
- 5
Steven Patrick Rowe
$103,063.02 across 66 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
Progenics Pharmaceuticals, Inc. ranks #283 of 1,925 by total payments (top 15% by spend) but spreads that money notably more broadly than its spend rank alone would suggest -- #1,123 of 1,838 by HHI (bottom 39% least concentrated), a wider distribution than most similarly sized payers.
View all 12 companies in this HHI neighborhood as a list
- 3B Medical, Inc. : $29.3K total payments, HHI 805
- ModernaTX, Inc. : $2.4M total payments, HHI 803
- Community Blood Center : $72.5K total payments, HHI 797
- Acrotech Biopharma Inc. : $317.9K total payments, HHI 793
- KaVo Dental Technologies LLC : $990.42 total payments, HHI 792
- Creo Medical Inc. : $263.8K total payments, HHI 789
- Progenics Pharmaceuticals, Inc. (this company) : $1.7M total payments, HHI 786
- ABB Con-Cise Optical Group LLC : $238.5K total payments, HHI 784
- Vantage Technology LLC : $593.80 total payments, HHI 784
- Vapotherm Inc : $135.8K total payments, HHI 783
- Genzyme Corporation : $57.6M total payments, HHI 783
- Heraeus Medical, LLC. : $35.7K total payments, HHI 783
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Progenics Pharmaceuticals, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Progenics Pharmaceuticals, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Progenics Pharmaceuticals, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Novocure GmbH
$4.8M 7 recipients
Compare payment profiles
Stemline Therapeutics Inc.
$4.7M 6,314 recipients
Compare payment profiles
Inspire Medical Systems, Inc.
$4.8M 51,283 recipients
Compare payment profiles
InSightec,LTD
$4.9M 2 recipients
Compare payment profiles
Blustone Synergy, LLC
$4.9M 0 recipients
Compare payment profiles
Put this to use
Progenics Pharmaceuticals, Inc. ranks #283 of 1,925 by all-tracks total payments, led by "Compensation for Services Other Than Consulting".
- See where Progenics Pharmaceuticals, Inc. sits among every top spender on the full leaderboard. Top 100 by total payments
- Compare "Compensation for Services Other Than Consulting" spend across every manufacturer, not just Progenics Pharmaceuticals, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.